Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158

Authors :: Stephen Chuan-Hao Kao
Bo Gao
Nicolas Penel
Willeke Ros
Sarina Anne Piha-Paul
Shadia I. Jalal
Lei Xu
Scott K. Pruitt
Jose A. Lopez-Martin
Hyun Cheol Chung
Jean-Pierre Delord
Maya Gottfried
Wilson H. Miller
Susan Zeigenfuss
Alona Zer
Aurélien Marabelle
Source :: Journal of Clinical Oncology. 36:8506-8506
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 8506Background: The antitumor activity of pembrolizumab, an IgG4 anti-PD-1 monoclonal antibody, was evaluated in patients (pts) with SCLC in KEYNOTE-158 (NCT02628067), a phase 2 basket study of 11 ...

Subjects :: 0301 basic medicine
Antitumor activity
Cancer Research
business.industry
medicine.drug_class
Phases of clinical research
Pembrolizumab
Monoclonal antibody
respiratory tract diseases
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Oncology
030220 oncology & carcinogenesis
Cancer research
Medicine
In patient
Non small cell
business

Tools